Clinical Trials Logo

Clinical Trial Summary

Prospective observations on safety of the herbal medicines regarding liver and kidney injuries at inpatient setting of four sites in South Korea which are located at each quadrant of the country. In a previous study (PMID 28634823), six women presented liver injuries by herbs and similar findings were also reported. That knowledge has been developed to design the observations of females (19-80 ages) at least 2 weeks' hospitalization with weekly routine lab tests to obtain the occurrence of liver or kidney injuries and the profiles on micro biomarkers throughout the hospitalization period, and then, the follow-up test will be conducted in outpatient setting.


Clinical Trial Description

Total 500 inpatients will be observed to assess safety of herbal medicines with the balance of 60 to 110 each site. After obtaining the informed consent from patient, blood draw and urine collection are conducted prior to intake of the herbal medicine, blood draw and urine collection are routinely done every week throughout the whole admission period. The primary outcomes are, 1) liver for alanine aminotransferase (ALT), RUCAM (in case of causality assessment when ALT≥3 upper normal limit) and new biomarker, mircoRNA-122 and 2) kidney for urine creatinine, blood urea nitrogen (BUN) and new biomarker, Neutrophil gelatinase-associated lipocalin (NGAL). The secondary outcomes are, 1) liver for aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma glutamyltransferase (γ-GT), total bilirubin and new biomarker, glutamate dehydrogenase (GLDH) and 2) kidney for serum creatinine and new biomarker, kidney injury molecule-1 (KIM-1). The follow-up will be done by the study doctors based on their decision on the inpatient after discharge. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04269486
Study type Observational
Source Korea Institute of Oriental Medicine
Contact
Status Active, not recruiting
Phase
Start date July 1, 2019
Completion date December 31, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT05738681 - Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial Phase 2/Phase 3
Completed NCT01000766 - Identifying Changes in Blood (Potential Biomarkers) in Individuals With Drug-Induced Liver Injury N/A
Recruiting NCT00360646 - Drug-Induced Liver Injury (DILI) Network Retrospective
Recruiting NCT05789797 - Remaxol® in Patients With Drug-induced Liver Injuries During Cancer Chemotherapy
Terminated NCT02686385 - Efficacy of N-acetylcysteine With or Without Steroids in Drug Induced Liver Injury N/A
Recruiting NCT06192589 - Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions Phase 1
Completed NCT00616018 - Acetaminophen Adduct Formation in Non-Drinkers Taking Therapeutic Doses of Acetaminophen for Ten Consecutive Days Phase 4
Withdrawn NCT01137591 - Acetaminophen in Combination With N-Acetylcysteine (NAC) Versus Placebo in Treating Fever N/A